pharmacodynamic synergism. Minor/Significance Unknown.indapamidetreprostinil increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown.isradipinetreprostinil increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown.ketanserintreprostinil increases effects of ketanserin by pharmacodynamic synergism. Minor/Significance Unknown.labetaloltreprostinil increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.lisinopriltreprostinil increases effects of lisinopril by pharmacodynamic synergism. Minor/Significance Unknown.maitakemaitake increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research).mecamylaminetreprostinil increases effects of mecamylamine by pharmacodynamic synergism. Minor/Significance Unknown.methyclothiazidetreprostinil increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown.metolazonetreprostinil increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown.metoprololtreprostinil increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.minoxidiltreprostinil increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown.moexipriltreprostinil increases effects of moexipril by pharmacodynamic synergism. Minor/Significance Unknown.moxisylytetreprostinil increases effects of moxisylyte by pharmacodynamic synergism. Minor/Significance Unknown.moxonidinetreprostinil increases effects of moxonidine by pharmacodynamic synergism. Minor/Significance Unknown.nadololtreprostinil increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown.nebivololtreprostinil increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown.nicardipinetreprostinil increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown.nifedipinetreprostinil increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown.nisoldipinetreprostinil increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown.penbutololtreprostinil increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown.perindopriltreprostinil increases effects of perindopril by pharmacodynamic synergism. Minor/Significance Unknown.phenoxybenzaminetreprostinil increases effects of phenoxybenzamine by pharmacodynamic synergism. Minor/Significance Unknown.phentolaminetreprostinil increases effects of phentolamine by pharmacodynamic synergism. Minor/Significance Unknown.pindololtreprostinil increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown.prazosintreprostinil increases effects of prazosin by pharmacodynamic synergism. Minor/Significance Unknown.propranololtreprostinil increases effects of propranolol by pharmacodynamic synergism. Minor/Significance Unknown.quinapriltreprostinil increases effects of quinapril by pharmacodynamic synergism. Minor/Significance Unknown.ramipriltreprostinil increases effects of ramipril by pharmacodynamic synergism. Minor/Significance Unknown.reishireishi increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown.shepherd's purseshepherd's purse, treprostinil. Other (see comment). Minor/Significance Unknown. Comment: Theoretically, shepherd's purse may interfere with BP control.silodosintreprostinil increases effects of silodosin by pharmacodynamic synergism. Minor/Significance Unknown.sotaloltreprostinil increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.spironolactonetreprostinil increases effects of spironolactone by pharmacodynamic synergism. Minor/Significance Unknown.terazosintreprostinil increases effects of terazosin by pharmacodynamic synergism. Minor/Significance Unknown.timololtreprostinil increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown.tizanidinetizanidine increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.torsemidetreprostinil increases effects of torsemide by pharmacodynamic synergism. Minor/Significance Unknown.trandolapriltreprostinil increases effects of trandolapril by pharmacodynamic synergism. Minor/Significance Unknown.triamterenetreprostinil increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.verapamiltreprostinil increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.zotepinetreprostinil increases effects of zotepine by pharmacodynamic synergism. Minor/Significance Unknown.acebutololMinor (1)treprostinil increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown.agrimonyMinor (1)agrimony increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown.aldesleukinMonitor Closely (1)aldesleukin increases effects of treprostinil by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.alfuzosinMinor (1)treprostinil increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.amifostineMonitor Closely (1)amifostine, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.amilorideMinor (1)treprostinil increases effects of amiloride by pharmacodynamic synergism. Minor/Significance Unknown.amlodipineMinor (1)treprostinil increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown.asenapineMinor (1)treprostinil increases effects of asenapine by pharmacodynamic synergism. Minor/Significance Unknown.atenololMinor (1)treprostinil increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown.benazeprilMinor (1)treprostinil increases effects of benazepril by pharmacodynamic synergism. Minor/Significance Unknown. Enhanced hypotensive effects.bendroflumethiazideMinor (1)treprostinil increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor/Significance Unknown.betaxololMinor (1)treprostinil increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown.bisoprololMinor (1)treprostinil increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown.bosentanMinor (1)treprostinil increases effects of bosentan by pharmacodynamic synergism. Minor/Significance Unknown.brimonidineMinor (1)brimonidine increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown.bumetanideMinor (1)treprostinil increases effects of bumetanide by pharmacodynamic synergism. Minor/Significance Unknown.candesartanMonitor Closely (1)treprostinil increases effects of candesartan by pharmacodynamic synergism. Use Caution/Monitor.cannabidiolMonitor Closely (1)cannabidiol will increase the level or effect of treprostinil by decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially inhibit CYP2C8 activity. Consider reducing the dose when concomitantly using CYP2C8 substrates.captoprilMinor (1)treprostinil increases effects of captopril by pharmacodynamic synergism. Minor/Significance Unknown. Both drugs lower blood pressure. Monitor blood pressure.carbidopaMonitor Closely (1)carbidopa increases effects of treprostinil by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.carvedilolMinor (1)treprostinil increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown.celiprololMinor (1)treprostinil increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown.chlorothiazideMinor (1)treprostinil increases effects of chlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.chlorthalidoneMinor (1)treprostinil increases effects of chlorthalidone by pharmacodynamic synergism. Minor/Significance Unknown.clevidipineMinor (1)treprostinil increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown.clonidineMinor (1)treprostinil increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown.cornsilkMinor (1)cornsilk increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown.cyclopenthiazideMinor (1)treprostinil increases effects of cyclopenthiazide by pharmacodynamic synergism. Minor/Significance Unknown.dabigatranMonitor Closely (1)dabigatran and treprostinil both increase anticoagulation. Use Caution/Monitor. Both drugs have the potential to cause bleeding. Concomitant use may increase risk of bleeding.dichlorphenamideMonitor Closely (1)dichlorphenamide and treprostinil both decrease serum potassium. Use Caution/Monitor.diltiazemMinor (1)treprostinil increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown.doxazosinMinor (1)treprostinil increases effects of doxazosin by pharmacodynamic synergism. Minor/Significance Unknown.drospirenoneMinor (1)treprostinil increases effects of drospirenone by pharmacodynamic synergism. Minor/Significance Unknown.eluxadolineMonitor Closely (1)eluxadoline increases levels of treprostinil by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates.enalaprilMinor (1)treprostinil increases effects of enalapril by pharmacodynamic synergism. Minor/Significance Unknown.eplerenoneMinor (1)treprostinil increases effects of eplerenone by pharmacodynamic synergism. Minor/Significance Unknown.epoprostenolMonitor Closely (1)epoprostenol, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.Minor (1)treprostinil increases effects of epoprostenol by pharmacodynamic synergism. Minor/Significance Unknown.eprosartanMonitor Closely (1)treprostinil increases effects of eprosartan by pharmacodynamic synergism. Use Caution/Monitor.esmololMinor (1)treprostinil increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown.ethacrynic acidMinor (1)treprostinil increases effects of ethacrynic acid by pharmacodynamic synergism. Minor/Significance Unknown.felodipineMinor (1)treprostinil increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown.fenoldopamMonitor Closely (1)fenoldopam, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.Minor (1)treprostinil increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.fish oil triglyceridesMonitor Closely (1)fish oil triglycerides will increase the level or effect of treprostinil by anticoagulation. Use Caution/Monitor. Prolonged bleeding reported in patients taking antiplatelet agents or anticoagulants and oral omega-3 fatty acids. Periodically monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet agents or anticoagulants.forskolinMinor (1)forskolin increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown.fosinoprilMinor (1)treprostinil increases effects of fosinopril by pharmacodynamic synergism. Minor/Significance Unknown.furosemideMinor (1)treprostinil increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.green teaMonitor Closely (1)green tea, treprostinil. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of bleeding.guanfacineMinor (1)treprostinil increases effects of guanfacine by pharmacodynamic synergism. Minor/Significance Unknown.hydralazineMonitor Closely (1)hydralazine, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.Minor (1)treprostinil increases effects of hydralazine by pharmacodynamic synergism. Minor/Significance Unknown.hydrochlorothiazideMinor (1)treprostinil increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown.ibrutinibMonitor Closely (1)ibrutinib will increase the level or effect of treprostinil by anticoagulation. Use Caution/Monitor. Ibrutinib may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies and monitor for signs of bleeding.iloprostMonitor Closely (1)iloprost, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.Minor (1)treprostinil increases effects of iloprost by pharmacodynamic synergism. Minor/Significance Unknown.imidaprilMinor (1)treprostinil increases effects of imidapril by pharmacodynamic synergism. Minor/Significance Unknown.indapamideMinor (1)treprostinil increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown.irbesartanMonitor Closely (1)treprostinil increases effects of irbesartan by pharmacodynamic synergism. Use Caution/Monitor.isradipineMinor (1)treprostinil increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown.ketanserinMinor (1)treprostinil increases effects of ketanserin by pharmacodynamic synergism. Minor/Significance Unknown.labetalolMinor (1)treprostinil increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown.levodopaMonitor Closely (1)levodopa increases effects of treprostinil by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.lisinoprilMinor (1)treprostinil increases effects of lisinopril by pharmacodynamic synergism. Minor/Significance Unknown.lofexidineSerious - Use Alternative (1)lofexidine, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.losartanMonitor Closely (1)treprostinil increases effects of losartan by pharmacodynamic synergism. Use Caution/Monitor.maitakeMinor (1)maitake increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research).maravirocMonitor Closely (1)maraviroc, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.mecamylamineMinor (1)treprostinil increases effects of mecamylamine by pharmacodynamic synergism. Minor/Significance Unknown.methyclothiazideMinor (1)treprostinil increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown.metolazoneMinor (1)treprostinil increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown.metoprololMinor (1)treprostinil increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown.mifepristoneMonitor Closely (1)mifepristone will increase the level or effect of treprostinil by Other (see comment). Use Caution/Monitor. Inhibits CYP2C8/2C9; use smallest recommended doses for substrates and monitorminoxidilMonitor Closely (1)minoxidil, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.Minor (1)treprostinil increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown.moexiprilMinor (1)treprostinil increases effects of moexipril by pharmacodynamic synergism. Minor/Significance Unknown.moxisylyteMinor (1)treprostinil increases effects of moxisylyte by pharmacodynamic synergism. Minor/Significance Unknown.moxonidineMinor (1)treprostinil increases effects of moxonidine by pharmacodynamic synergism. Minor/Significance Unknown.nadololMinor (1)treprostinil increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown.nebivololMinor (1)treprostinil increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown.nicardipineMinor (1)treprostinil increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown.nifedipineMinor (1)treprostinil increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown.nisoldipineMinor (1)treprostinil increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown.olmesartanMonitor Closely (1)treprostinil increases effects of olmesartan by pharmacodynamic synergism. Use Caution/Monitor.omaveloxoloneMonitor Closely (1)omaveloxolone will decrease the level or effect of treprostinil by Other (see comment). Use Caution/Monitor. Omaveloxolone may reduce systemic exposure of sensitive CYP2C8 substrates. Check prescribing information of substrate if dosage modification is needed. penbutololMinor (1)treprostinil increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown.perindoprilMinor (1)treprostinil increases effects of perindopril by pharmacodynamic synergism. Minor/Significance Unknown.phenoxybenzamineMinor (1)treprostinil increases effects of phenoxybenzamine by pharmacodynamic synergism. Minor/Significance Unknown.phentolamineMinor (1)treprostinil increases effects of phentolamine by pharmacodynamic synergism. Minor/Significance Unknown.pindololMinor (1)treprostinil increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown.prazosinMinor (1)treprostinil increases effects of prazosin by pharmacodynamic synergism. Minor/Significance Unknown.propranololMinor (1)treprostinil increases effects of propranolol by pharmacodynamic synergism. Minor/Significance Unknown.quinaprilMinor (1)treprostinil increases effects of quinapril by pharmacodynamic synergism. Minor/Significance Unknown.ramiprilMinor (1)treprostinil increases effects of ramipril by pharmacodynamic synergism. Minor/Significance Unknown.reishiMinor (1)reishi increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown.sacubitril/valsartanMonitor Closely (1)treprostinil increases effects of sacubitril/valsartan by pharmacodynamic synergism. Use Caution/Monitor.shepherd's purseMinor (1)shepherd's purse, treprostinil. Other (see comment). Minor/Significance Unknown. Comment: Theoretically, shepherd's purse may interfere with BP control.silodosinMinor (1)treprostinil increases effects of silodosin by pharmacodynamic synergism. Minor/Significance Unknown.sotalolMinor (1)treprostinil increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown.spironolactoneMinor (1)treprostinil increases effects of spironolactone by pharmacodynamic synergism. Minor/Significance Unknown.stiripentolMonitor Closely (1)stiripentol will increase the level or effect of treprostinil by Other (see comment). Modify Therapy/Monitor Closely. Stiripentol is a CYP2C8 inhibitor. Consider dosage reduction for CYP2C8 substrates if adverse effects are experienced when coadministered.tecovirimatMonitor Closely (1)tecovirimat will increase the level or effect of treprostinil by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Tecovirimat is a weak inhibitor of CYP2C8 and CYP2C19. Monitor for adverse effects if coadministered with sensitive substrates of these enzymes.telmisartanMonitor Closely (1)treprostinil increases effects of telmisartan by pharmacodynamic synergism. Use Caution/Monitor.terazosinMinor (1)treprostinil increases effects of terazosin by pharmacodynamic synergism. Minor/Significance Unknown.teriflunomideMonitor Closely (1)teriflunomide increases levels of treprostinil by Other (see comment). Use Caution/Monitor. Comment: Teriflunomide inhibits CYP2C8; caution when coadministered with CYP2C8 substrates.timololMinor (1)treprostinil increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown.tizanidineMinor (1)tizanidine increases effects of treprostinil by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.torsemideMinor (1)treprostinil increases effects of torsemide by pharmacodynamic synergism. Minor/Significance Unknown.trandolaprilMinor (1)treprostinil increases effects of trandolapril by pharmacodynamic synergism. Minor/Significance Unknown.triamtereneMinor (1)treprostinil increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown.valsartanMonitor Closely (1)treprostinil increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor.verapamilMinor (1)treprostinil increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.xipamideMonitor Closely (1)xipamide increases effects of treprostinil by pharmacodynamic synergism. Use Caution/Monitor.zotepineMinor (1)treprostinil increases effects of zotepine by pharmacodynamic synergism. Minor/Significance Unknown. >10% Infusion site reaction, pain (80-85%) Headache (27-41%) Nausea (19-22%) Diarrhea (20-30%) Vasodilation (10-20%) Jaw pain (13%) Rash (10-20%) 1-10% Dizziness 9%) Edema (9%) Pruritis (8%) Hypotension (4%) Frequency Not Defined Angioedema Bone pain Restlessness Cellulitis Haemoptysis Postmarketing Reports Dyspepsia Vomiting Myalgia/muscle spasm Arthralgia Syncope Pain extremity Gastrointestinal effects Injectable Thrombophlebitis associated with peripheral IV infusion, thrombocytopenia, bone pain, pruritus, dizziness, arthralgia, myalgia/muscle spasm, and pain in extremity Generalized rashes, sometimes macular or papular in nature, and cellulitis have been infrequently reported Contraindications Extended-release tablets: Severe hepatic impairment (Child Pugh Class C) Injectable: None Cautions Hepatic/renal impairment (titrate up slowly); such patients will likely be exposed to